press-releases

May 13, 2025, 16:05 ET Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif., May 13, 2025 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results […]

Mar 26, 2025, 16:05 ET Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO,

Mar 19, 2025, 16:30 ET CUPERTINO, Calif., March 19, 2025 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full

Feb 04, 2025, 07:30 ET CUPERTINO, Calif., Feb. 4, 2025 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, to be held virtually, February 11-12, 2025. Presentation details are as follows: Date and time:         Tue, Feb

Jan 28, 2025, 10:09 ET The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company’s planned Phase 3 trial CUPERTINO, Calif., Jan. 28, 2025 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM

Nov 25, 2024, 06:00 ET CUPERTINO, Calif., Nov. 25, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co.

Nov 13, 2024, 16:01 ET –     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation –     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the

Nov 06, 2024, 16:45 ET CUPERTINO, Calif., Nov. 6, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13,

Oct 17, 2024, 08:30 ET CUPERTINO, Calif., Oct. 17, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver

Sep 25, 2024, 08:00 ET – Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design – Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation  – Protocol for Phase 3